Key facts
- This page summarizes Laura Sepp-Lorenzino's Form 4 filing for Intellia Therapeutics, Inc. (NTLA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jan 2025, 16:30.
Laura Sepp-Lorenzino - 01 Jan 2025 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)
- Reporting relationship
- EVP, Chief Scientific Officer
- Issuer ticker
- NTLA
- Reported as of
- 01 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2025, 16:30:05 UTC
- Prior SEC filing
- 31 May 2024
- Next SEC filing
- 07 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- James Basta, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Laura Sepp-Lorenzino filed Form 4 for Intellia Therapeutics, Inc. (NTLA) on 03 Jan 2025.
Change
- Previous filing in this sequence was filed on 31 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NTLA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,500
- Change %
- +4.2%
- Price
- Shares after
- 86,354
- Date
- 01 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NTLA
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -3,500
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,500
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Footnote F2
Includes 405 and 556 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2024 and December 31, 2024, respectively.
Footnote F3
On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.